LAKESHORE BIOPHARMA CO LTD (LSB)
KYG9845F1090 - Common Stock
LSB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of LSB have multiple concerns. LSB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
LSB had negative earnings in the past year.
LSB had a negative operating cash flow in the past year.
1.2 Ratios
The Return On Assets of LSB (-28.65%) is better than 70.44% of its industry peers.
Looking at the Return On Equity, with a value of -74.07%, LSB is in line with its industry, outperforming 55.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.65% | ||
| ROE | -74.07% | ||
| ROIC | N/A |
ROA(3y)-15.14%
ROA(5y)N/A
ROE(3y)-37.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LSB has a Gross Margin of 79.48%. This is amongst the best in the industry. LSB outperforms 86.73% of its industry peers.
The Profit Margin and Operating Margin are not available for LSB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LSB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LSB has been increased compared to 1 year ago.
Compared to 1 year ago, LSB has an improved debt to assets ratio.
2.2 Solvency
LSB has an Altman-Z score of -2.06. This is a bad value and indicates that LSB is not financially healthy and even has some risk of bankruptcy.
LSB's Altman-Z score of -2.06 is in line compared to the rest of the industry. LSB outperforms 53.10% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that LSB is not too dependend on debt financing.
LSB's Debt to Equity ratio of 0.17 is on the low side compared to the rest of the industry. LSB is outperformed by 67.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.06 |
ROIC/WACCN/A
WACC9.67%
2.3 Liquidity
A Current Ratio of 1.13 indicates that LSB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.13, LSB is doing worse than 85.84% of the companies in the same industry.
A Quick Ratio of 0.87 indicates that LSB may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.87, LSB is doing worse than 87.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
LSB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.08%.
The Revenue for LSB has decreased by -16.56% in the past year. This is quite bad
EPS 1Y (TTM)-33.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.62%
Revenue 1Y (TTM)-16.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.3%
3.2 Future
LSB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.50% yearly.
LSB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.61% yearly.
EPS Next Y45.9%
EPS Next 2Y42.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year32.68%
Revenue Next 2Y52.65%
Revenue Next 3Y-24.94%
Revenue Next 5Y-10.61%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
LSB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LSB's earnings are expected to grow with 42.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for LSB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LAKESHORE BIOPHARMA CO LTD
NASDAQ:LSB (12/20/2024, 8:22:55 PM)
After market: 3 +0.04 (+1.35%)2.96
+0.26 (+9.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.95%
Inst Owner ChangeN/A
Ins Owners29.8%
Ins Owner ChangeN/A
Market Cap56.48M
Analysts80
Price Target31.62 (968.24%)
Short Float %0.84%
Short Ratio0.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-86.46%
Min EPS beat(2)-128.75%
Max EPS beat(2)-44.17%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.4%
Min Revenue beat(2)-15.22%
Max Revenue beat(2)14.42%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)642.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)-900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.7 | ||
| P/tB | 0.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.56
EYN/A
EPS(NY)-2.46
Fwd EYN/A
FCF(TTM)-2.44
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS4.12
BVpS4.2
TBVpS3.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.65% | ||
| ROE | -74.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.48% | ||
| FCFM | N/A |
ROA(3y)-15.14%
ROA(5y)N/A
ROE(3y)-37.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 104.9% | ||
| Cap/Sales | 7.72% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | -2.06 |
F-Score3
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)406.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.62%
EPS Next Y45.9%
EPS Next 2Y42.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.3%
Revenue Next Year32.68%
Revenue Next 2Y52.65%
Revenue Next 3Y-24.94%
Revenue Next 5Y-10.61%
EBIT growth 1Y-106.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.8%
OCF growth 3YN/A
OCF growth 5YN/A